Machine-learning pipeline identifies antimicrobial hexapeptides
A sequential machine-learning pipeline screened virtual libraries of 6–9-residue peptides and identified three leading antimicrobial hexapeptides. The paper reports activity against multidrug-resistant clinical isolates and therapeutic effects in a mouse bacterial-pneumonia model. These are laboratory and animal results, not clinical efficacy.
Technology: Sequential machine-learning pipeline for peptide selection, classification, ranking and activity regression
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors report a sequential machine-learning pipeline over virtual 6–9 amino-acid sequence space; the leading three identified hexapeptides were tested against clinical multidrug-resistant isolates and in a mouse bacterial-pneumonia model.
- Still unknown: The mouse model and reported comparison with penicillin do not establish human efficacy. The PubMed primary metadata gives journal online date 2023-01-12; no earlier pre-2020 version is identified in the reviewed primary material.
- AI role: Sequential learned modules selected, classified, ranked and regressed peptide candidates from the virtual sequence library; the reported three lead hexapeptides are outputs of that workflow.
Evidence sources: https://www.nature.com/articles/s41551-022-00991-2 · https://pubmed.ncbi.nlm.nih.gov/36635418/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary Nature indexed article text and PubMed abstract/metadata/affiliation record for the ML hexapeptide screening study, its January 2023 publication date and reported mouse pneumonia assays..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.